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Introduction
Angiosarcoma is a neoplasm of an endothelial origin, which 
could arise from blood or lymphatic vessels, respectively he-
mangiosarcoma or lymphosarcoma. They account for only 0.1% 
of adult malignancies and represent 1–2% of all soft tissue sar-
comas in humans [1]. Most tumours are malignant and readily 
give distant metastases because they are composed of rapidly 
proliferating and extensively infiltrating anaplastic cells. They can 
occur in any organ of the body and the most common form is a cu-
taneous angiosarcoma [2]. We report a PET-CT study of a rare 
case of cardiac angiosarcoma, which was initially misdiagnosed 
as heart inflammation.
Case report
The 30 year old male with heart angiosarcoma was referred 
for PET-CT with 18FDG study. The patient had had no significant 
medical history and at the beginning was hospitalised because of 
a continuos pain in the pericardial region, initially misdiagnosed 
as pericarditis. The performed CAT scan showed pathological 
mass in the right atrium. The patient was subsequently subjected 
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to a surgical tumour resection but it occurred inoperable. The 
histo-pathology examination performed after biopsy revealed a well 
differentiated cardiac angiosarcoma with an adhesion molecule 
CD31 and a CD34 expression. After three courses of adjuvant 
chemotherapy consisted of Adriamycin (20 mg), Dacarbazine 
(200 mg) and Cyclophosphamide (100 mg) the patient was re-
ferred to the PET-CT Centre for treatment efficiency assessment [3]. 
The PET-CT study was performed according to a standard 
protocol: 2.5 minutes acquisition per bed position (GE DiscoveryTM 
STE PET-CT scanner), 45 minutes after 5MBq per kilogram body 
mass 18FDG injection proceeded by a six hours fasting period 
[4]. It revealed an intensive metabolic activity (SUVmax = 10.3) 
in the tumour mass surrounding right atrium cavity (Figure 1). 
The maximum thickness of the neoplasmatically-infiltrated atrium 
located in its basal part amounted to 30 mm. Concomitant pericar-
dial effusion was noticed. In addition, multiple metabolically active 
(up to SUVmax = 9.2) metastases were found in the skeleton (not 
visible on the CT scan) with no evidence of pulmonary or other 
soft tissue involvement (Figure 2).
Discussion
There are only few case reports concerning PET-CT with 18FDG 
in cardiac angiosarcoma. They are proving its usefulness in as-
sessing malignant potential of the tumour mass and exploration 
for distant metastases in primary diagnosis together with meta-
bolic response to and detection of local recurrence after applied 
therapy [5–8]. In the presented case PET-CT with 18FDG depicted 
persisted high metabolic activity in the tumour mass despite 
three courses of adjuvant chemotherapy and metabolically active 
metastases in the skeleton, not visible on previously scheduled 
imaging studies.
Conclusion
The PET-CT study with 18FDG could be of great value for 
angiosarcoma staging and predicting of the metabolic response 
to the applied chemotherapy regimen. 
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Figure 1. The 18FDG PET-CT study of a patient with cardiac angiosarcoma. A. Axial; B. Coronal; C. Sagittal slices
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Figure 2. The 18FDG PET-CT study of a patient with cardiac angiosarcoma depicting both heart and skeletal involvement. A. MIP lateral projection; 
B. Combined PET-CT studies; C. CT study
